Included in the formulation
АТХ:B.02.B.D.04 Coagulation factor IX
Pharmacodynamics:Recombinant single-chain glycoprotein, similar in composition to the endogenous clotting factor IX. Activated by interacting with the tissue factor complex of the external coagulation system - VII factor and XI factor of the internal coagulation system, after which it activates the X factor of coagulation. As a result, fibrinogen is converted into fibrin and the formation of a blood clot.
Pharmacokinetics:After intravenous administration, the elimination half-life is 16-30 hours. Elimination by the kidneys.
Indications:It is used to treat and prevent bleeding in patients with hemophilia B.
III.D65-D69.D67 Hereditary deficiency of factor IX
IV.E50-E64.E56.1 Insufficiency of vitamin K
XXI.Z100.Z100 * CLASS XXII Surgical Practice
Contraindications:The syndrome of disseminated intravascular coagulation, fibrinolysis, age up to 3 years, individual intolerance.
Carefully:Pregnancy and lactation, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:Intravenous bolus, the initial dose is calculated as follows: 1 IU of the drug for each kg of body weight is accompanied by an increase in coagulation factor IX on 0.9 IU / dl, that is, 0.9% of the norm.
When hemorrhage is administered from 20 to 100 IU until the bleeding stops.
For the prevention of - 30-60 IU / kg of weight 2 times a week.
Side effects:Local Reactions: burning sensation at the injection site.
General reactions: hyperthermia.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described. It is forbidden to mix the drug with other medicines in one solution, a syringe, infusion set.
Special instructions:When taking the drug is not recommended driving and working with moving machinery.